Argenx Se (ARGX) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
argenx SE has announced the FDA approval of VYVGART Hytrulo, a groundbreaking treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), offering new hope to patients with this rare autoimmune disease. This first-of-its-kind treatment, which is administered through weekly injections, has demonstrated significant clinical improvements in the ADHERE trial, with a 61% reduction in the risk of relapse. With the commitment to make the drug immediately accessible in the U.S., argenx SE is providing a transformative new option for individuals affected by CIDP.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.